ubmslatePT-logo-ubm

PT Mobile Logo

Search form

Topics:

Update on Bipolar Disorder, Part 2: Bipolar Depression and Cyclothymic Disorder

Update on Bipolar Disorder, Part 2: Bipolar Depression and Cyclothymic Disorder

FDA-approved indications for pharmacological management of bipolar depressionTable – FDA-approved indications for pharmacological management of bip...
Treatment Strategy for Acute Bipolar DepressionFigure. Treatment Strategy for Acute Bipolar Depression

Premiere Date: December 20, 2015
Expiration Date: June 20, 2017

This activity offers CE credits for:
1. Physicians (CME)
2. Other

ACTIVITY GOAL

This article reviews DSM-5 changes to symptom criteria for bipolar disorder. The primary focus is on treatment of bipolar depression and cyclothymic disorder.

LEARNING OBJECTIVES

At the end of this CE activity, participants should be able to:

• Identify the 4 FDA-approved medications for bipolar depression

• Identify FDA-approved medication for maintenance therapy of depression in bipolar disorder

• Distinguish which antidepressants to avoid to minimize the risk of mood destabilization

TARGET AUDIENCE

This continuing medical education activity is intended for psychiatrists, psychologists, primary care physicians, physician assistants, nurse practitioners, and other health care professionals who seek to improve their care for patients with mental health disorders.

CREDIT INFORMATION

CME Credit (Physicians): This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CME Outfitters, LLC, and Psychiatric Times. CME Outfitters, LLC, is accredited by the ACCME to provide continuing medical education for physicians.

CME Outfitters designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to Nurse Practitioners and Physician Assistants: AANPCP and AAPA accept certificates of participation for educational activities certified for 1.5 AMA PRA Category 1 Credit™.

DISCLOSURE DECLARATION

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer-review process.

The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Philip G. Janicak, MD, reports that he has received grant support from, and is on the speakers bureau for, Neuronetics Inc, Sunovion, and Ortho-McNeil/Janssen; he is also a consultant for Neuronetics Inc.

Joseph Esposito, MS, MD, has no disclosures to report.

Michael Gilin, MD, (peer/content reviewer) reports that he is on the speakers bureau for Otsuka.

Applicable Psychiatric Times staff and CME Outfitters staff have no disclosures to report.

UNLABELED USE DISCLOSURE

Faculty of this CME/CE activity may include discussion of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, and the faculty do not endorse the use of any product outside of the FDA-labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767)

Pages

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.